#ES­MO22: As­traZeneca takes dif­fer­ent ap­proach to CT­LA-4 with bis­pe­cif­ic — but tox­i­c­i­ties re­main high

PARIS — Dur­ing a Sun­day morn­ing ES­MO pre­sen­ta­tion ses­sion on non-small cell lung can­cer in which the over­flow sec­tion over­flowed, As­traZeneca took the first two pre­sen­ta­tions, giv­ing an up­date on two drugs. First came En­her­tu, its HER2-tar­get­ed an­ti­body drug con­ju­gate, which post­ed sim­i­lar re­sults to those that won it an ac­cel­er­at­ed ap­proval in a tiny sub­group of NSCLC pa­tients in Au­gust.

Sec­ond, As­traZeneca pre­sent­ed on one of its ear­ly-stage prospects, ME­DI5752. A rel­ic of the Med­Im­mune name which the phar­ma re­tired in 2019, ME­DI5752 is a bis­pe­cif­ic that tar­gets two well-known im­mune check­points: CT­LA-4 and PD-1.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER